Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Inclusion Criteria: Histologically confirmed supratentorial grade IV astrocytoma Glioblastoma multiforme Subtotal resection or biopsy with measurable and contrast-enhancing disease on the postoperative, pretreatment MRI/CT scan Performance status - Karnofsky 60-100% Absolute neutrophil count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Hemoglobin at least 9.0 g/dL Bilirubin normal Creatinine normal Creatinine clearance at least 60 mL/min Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No serious concurrent infection or medical illness that would jeopardize ability to receive protocol chemotherapy with reasonable safety No other prior malignancy within the past 5 years except curatively treated carcinoma in situ or basal cell skin cancer No grade 2 or greater pre-existing sensory neuropathy No history of allergy to platinum compounds or to antiemetics appropriate for administration in conjunction with protocol chemotherapy Mini mental score at least 15 No prior immunotherapy for glioblastoma multiforme No prior biologic therapy for glioblastoma multiforme, including: Immunotoxins Immunoconjugates Antiangiogenesis compounds Antisense Peptide receptor antagonists Interferons Interleukins Tumor infiltrating lymphocytes Lymphokine activated killer cells Gene therapy No concurrent filgrastim (G-CSF) No prior chemotherapy for glioblastoma multiforme No prior hormonal therapy for glioblastoma multiforme Prior glucocorticoid therapy for glioblastoma multiforme allowed Must be maintained on a stable (lowest required dose) corticosteroid regimen for at least 5 days before and during study No concurrent dexamethasone as an antiemetic No prior radiotherapy for glioblastoma multiforme Recovered from immediate postoperative period At least 10 days since prior anticonvulsant drug that induces hepatic metabolic enzymes No other concurrent investigational agents